The company has announced a capex of | 100-110 crore for the five proprietary products, which it will supply to SCC Japan. The asset turn is expected to be between 2x and 2.5x. Out of the five molecules, one is expected to be commercialised by Q2FY22E while the remaining four would be altogether by the end of FY22 or beginning of FY23E. The management envisaged that they are setting up a capacity of 350 tonnes per year initially for one molecule, which is ~33% of the size of SCC Japan's consumption and, thus, bodes well for another expansion in coming years. We expect that...